TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Seroma Reduction and Drain Free Mastectomy
Brief Summary: To prove that omitting drains after mastectomy and flap fixation does not contribute to higher incidence of seroma formation and therefore reducing patient disutility such as seroma aspirations and visits to the outpatient clinic, as well as reducing seroma related wound complications.


Options:
A: Inclusion Criteria:

* Written informed consent
* Coronary heart disease patients to transplant more than 2 vascular bridge
* The thigh groin following from the saphenous vein

Exclusion Criteria:

* Subjects does not agree to participate in clinical trials
* Subjects had a injury, operation history of Thigh
* Subjects having ever received chemotherapy before the surgery
* Subjects with known hypersensitivity to components of the surgical sticky membrane
B: Inclusion Criteria:

* Older than 18 years
* Female sex
* Indication for mastectomy

Exclusion Criteria:

* Patients undergoing breast conserving therapy
* Patients undergoing modified radical mastectomy
* Patients undergoing direct breast reconstruction
* Unable to comprehend implications and extent of study and sign for informed consent
* Patients with radiation therapy of unilateral breast in previous history
C: Inclusion Criteria:

* All patients over the age of 18 years of age undergoing a laparotomy are eligible for entry into this study. Benign and malignant conditions are eligible for inclusion.

Exclusion Criteria:

* Pregnant patients and those undergoing re-look laparotomies are to be excluded.
D: Inclusion Criteria

* Gestational age ≥23weeks
* BMI≥30 Pre-pregnancy or BMI at first prenatal visit
* Planned or unplanned cesarean delivery

Exclusion Criteria:

* Non-availability for postoperative follow-up
* Contraindication to NPWT applicable to women undergoing cesarean: Pre-existing infection around incision site, Bleeding disorder, Therapeutic anticoagulation, Irradiated skin, Allergy to any component of the dressing (e.g. silver, acrylic, silicone, adhesive tape)

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Patient Work of Breathing and Tidal Volumes With High-flow Nasal Cannula Oxygen Therapy and Non-invasive Ventilation After Extubation in the ICU: a Prospective, Randomized, Controlled Study
Brief Summary: This study is aimed at evaluating patient work of breathing and tidal volumes with three methods of oxygenation: standard oxygen, high-flow oxygen therapy and non-invasive ventilation.


Options:
A: Inclusion Criteria:

* Age: 0-18 months
* Mechanical Ventilation via an endotracheal tube
* Elective surgery
* Post-bypass procedure
* Rachs 2 and above

Exclusion Criteria:

* Presence of major congenital malformations
* Presence of neuromuscular disease
* Presence of non drained pneumothorax
* Absent respiratory drive or recurrent apneas
* Hemodynamic instability
* Glasgow coma score (GCS) less than 8
* ECG with evidence of ischaemia or arrhythmias
* Active bleeding
B: Inclusion Criteria:

* Clinical diagnosis of bronchiolitis defined as the first viral episode of respiratory distress before 2 years of aging, presenting with rhinitis, tachypnea, cough, wheezing, prolonged expiratory time, crackles and use of accessory muscles, with or without fever, with or without infiltrate on the chest X ray
* bronchiolitis severity Wang modified score ≥ 10

Exclusion Criteria:

* recurrent wheezing
* heart disease
* chronic lung disease
* neuromuscular disease
* primary diagnosis was not bronchiolitis (pneumonia, pertussis)
* critically ill infants who had an immediate need of intubation
C: Inclusion Criteria:

* 1) receiving NCPAP ventilatory support at \> 72 hrs. of age and 2) requiring FiO2 21-50% on NCPAP.

Exclusion Criteria:

* FiO2 \>50%, presence of pneumothorax or pleural effusion, anatomical abnormalities of the airway, lungs, or esophagus, or cyanotic congenital heart defect.
D: Inclusion Criteria:

* Minimum age: 18 years
* planned extubation decided by the physician in charge of the patient after success of weaning trial
* patients at high risk of reintubation according to the following criteria: patient older than 65 years, or those having any underlying chronic cardiac or lung disease
* Hypoxemia defined by PaO2/FiO2 \< 300 mmHg under mechanical ventilation before extubation

Exclusion Criteria:

* Duration of mechanical ventilation prior to extubation \< 24h
* Contraindication to NIV
* Contraindication to nasogastric tube
* Do-not-reintubated order at time of extubation
* People under legal protection
* Opposition to participate

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Reduction of Visual and Auditory Stimuli to Reduce Pain During Venipuncture in Premature Infants. A Randomized Controlled Trial.
Brief Summary: The aim of the study is: To evaluate the efficacy of the reduction of visual and auditory stimuli on pain during venipuncture in premature newborns of 32-36 weeks of gestation.


Options:
A: Inclusion Criteria:

* Infants born preterm at Stanford Children's Hospital between 24 0/7 - 31 6/7 weeks gestational age

Exclusion Criteria:

* Congenital anomalies
* Recognizable malformation syndromes
* Active seizure disorders
* History of Central Nervous System infections
* Hydrocephalus
* Major sensori-neural hearing loss
* Likelihood to be transferred from NICU to alternate care facility or home environment prior to 36 weeks PMA and/or brain MRI scan
* Intraventricular Hemorrhage Grades III-IV
* Cystic periventricular leukomalacia (PVL)
* Surgical treatment for necrotizing enterocolitis
* Small for gestational age (SGA) \<3 percentile and/or Intra-uterine growth restriction (IUGR) no head sparing
* Twin-to-twin transfusions
B: Inclusion Criteria:

* • GA between 25+0 and 32 +6 weeks at birth

  * Apgar score: ≥ 7 at 10 minutes
  * Birth weight: \>3th centile and \<97th centile
  * Birth cranial circumference: \>10th centile
  * Periventricular leukomalacia (PVL) grade 1
  * Intraventricular haemorrhage (IVH) grade 1-2
  * Hypoglycaemia
  * Hyponatremia acceptable, provided they are not persistent and severe
  * Hypocalcaemia

Exclusion Criteria:

* • PVL, grade III and IV

  * IVH, grade III and IV
  * Sepsis (vertical and horizontal)
  * Congenital malformations and/or genetic abnormalities
  * Need of respiratory support with high flow/nCPAP
  * Repeated apnoea associated with bradycardia and fall of saturation
  * Hyaline membrane disease
  * Respiratory Distress Syndrome
  * Hyperbilirubinemia, requiring exchange transfusions during hospitalization
  * Lack of informed consent signed by the parents

The exclusion criteria for the mothers will be:

* Presence of depressive symptoms
* Drug abuse
* Age ˂18 years
C: Inclusion Criteria:

* Premature babies born between 32 and 36 weeks of gestation (both included).
* Haemodynamically stable.
* Require venipuncture and whose.
* Parents or legal guardians have signed informed consent forms.

Exclusion Criteria:

* Gestational age inferior to 32 weeks.
* Treated with intravenous or oral analgesics, sedatives or relaxants.
* Critical status or haemodynamically unstable.
* Requiring invasive mechanical ventilation.
D: Inclusion Criteria:

* Hospitalization at a study location
* Postmenstrual age of 32 weeks 0 days gestation to 36 weeks 0 days gestation

Exclusion Criteria:

* Ventilation using an endotracheal tube
* Major congenital malformations
* Family history of genetic hearing loss
* Use of sedatives or seizure medications

Secondary Study Inclusion Criteria:

* Enrolled in the control group of the main study

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: The prevalence of obesity in children is reaching epidemic proportions. Excess adiposity is more than just a cosmetic problem, having substantial metabolic consequences. Insulin resistance, hyperinsulinemia, impaired glucose tolerance, and frank diabetes are often seen in obese children. In this study the prevalence of impaired glucose (carbohydrate) tolerance in lean children with a family history of diabetes and obese children with acanthosis nigricans with or without a family history of diabetes mellitus will be studied.


Options:
A: Median overall survival time (36 months)
B: Overall Survival (2 years)
C: Time to progression (TTP) (At 1, 3, 6, 12 months and every 6 months thereafter)
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Correction of Myopia Evaluation Trial (COMET)
Brief Summary: To evaluate whether progressive addition lenses (PALs) slow the rate of progression of juvenile-onset myopia (nearsightedness) when compared with single vision lenses, as measured by cycloplegic autorefraction. An additional outcome measure is axial length, as measured by A-scan ultrasonography.

To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses).


Options:
A: Spherical equivalent refraction determined by cycloplegic autorefraction
B: Progression of myopia, determined by cycloplegic autorefraction
C: Cycloplegic autorefraction (Baseline, 6, 12, 18, and 24 months)
D: Determine the change in cycloplegic axial length in the study and control groups (2 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Correction of Myopia Evaluation Trial (COMET)
Brief Summary: To evaluate whether progressive addition lenses (PALs) slow the rate of progression of juvenile-onset myopia (nearsightedness) when compared with single vision lenses, as measured by cycloplegic autorefraction. An additional outcome measure is axial length, as measured by A-scan ultrasonography.

To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses).


Options:
A: N/A
B: the progression of myopia degree, axial length elongation of eye
C: Progression of myopia, determined by cycloplegic autorefraction
D: Determine the change in cycloplegic axial length in the study and control groups (2 years)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the relative efficacy of orthokeratology, primarily by assessment of changes in central corneal thickness, astigmatism, visual acuity, endothelial cell density, and corneal curvature.

To evaluate the relative safety of orthokeratology, primarily by assessment of changes in central corneal thickness, astigmatism, visual acuity, endothelial cell density, induced corneal edema, and epithelial staining.

To assess the duration of any orthokeratology treatment effect.

To study the mechanisms by which refractive error and visual acuity changes occur, in particular the contribution that comes from changes in corneal curvature and shape.

To determine whether there were any predisposing ocular factors that could be used to predict which subjects will experience changes or complications.


Options:
A: N/A
B: N/A
C: Axial length (every 6 monthly in 2 years)
D: the progression of myopia degree, axial length elongation of eye

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To test the hypothesis that correction with bifocal spectacle lenses rather than single-vision lenses will slow the progression of myopia in children with near-point esophoria. The primary outcome variable is cycloplegic refraction as measured with an automated refractor. Axial length is measured with ultrasound in order to test the corollary hypothesis that use of bifocals will slow ocular growth in these myopic children. We will also examine the amount of close work performed by subjects and the degree of parental myopia as factors that may influence myopia progression.


Options:
A: N/A
B: Axial growth
C: Cycloplegic refraction (1 year)
D: Myopia progression, measured by cycloplegic autorefraction (Every 6 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.

To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).

To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.


Options:
A: RT-PCR for influenza A virus in nasal secretion (2 days)
B: N/A
C: Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12 (Baseline (screening) and Month 12.); Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity (From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).)
D: Growth of Geographic Atrophy (6 months); Decrease in Drusen Volume (6 Months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.

To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).

To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.


Options:
A: N/A
B: N/A
C: N/A
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.

To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).

To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.


Options:
A: N/A
B: change in best-corrected visual acuity (6 months)
C: N/A
D: N/A

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982.

To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E.

To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.


Options:
A: Prostate cancer (Ongoing); Total cancer (Ongoing); Major cardiovascular events (Ongoing)
B: N/A
C: Retinal blood flow (in total 8x on 2 study days)
D: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. (2 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available

Extended Follow up of Study Patients

* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care


Options:
A: The primary outcome measure was logMAR visual acuity, measured 6-weekly for 18 weeks in refractive adaptation phase. In occlusion phase measured 2-weekly until no further gains
B: Visual acuity in the amblyopic eye (6 months)
C: Visual Acuity of the Amblyopic Eye HOTV (for children <7 y) or ETDRS for children 7+y (2 weeks (for strabismic, anisometropic, and combined mechanism amblyopia); 4 weeks (for deprivation amblyopia))
D: Change in Distance Visual Acuity From Baseline in the Younger Cohort (5 to <13 Years) (Baseline and 16 weeks); Mean Amblyopic Eye Visual Acuity (Younger Cohort) (16 Weeks from baseline); Mean Change in Amblyopic-eye Visual Acuity in the Older Cohort (13 to <17 Years) (Baseline and 16 weeks); Mean Amblyopic-eye Visual Acuity in the Older Cohort (13 to <17 Years) (16 weeks); Distribution of Change in Amblyopic-eye Visual Acuity (Baseline and 16 weeks); Distribution of Amblyopic-eye Visual Acuity (At 16 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available

Extended Follow up of Study Patients

* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care


Options:
A: Visual acuity in the amblyopic eye (6 months)
B: The primary outcome measure was logMAR visual acuity, measured 6-weekly for 18 weeks in refractive adaptation phase. In occlusion phase measured 2-weekly until no further gains
C: Visual acuity (8 weeks)
D: Distribution of Visual Acuity in the Amblyopic Eye at 17 Weeks (17 weeks); Mean Visual Acuity in the Amblyopic Eye at 17 Weeks (17 weeks); Distribution of Change in Visual Acuity in the Amblyopic Eye From Baseline to 17 Weeks (Baseline to 17 weeks); Mean Change in Visual Acuity in the Amblyopic Eye From Baseline to 17 Weeks (Baseline to 17 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available

Extended Follow up of Study Patients

* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care


Options:
A: Distribution of Amblyopic Eye Visual Acuity at 10 Weeks (10 Weeks); Mean (SD) Distribution of Visual Acuity at 10 Weeks (10 Weeks); Distribution of Amblyopic Eye Visual Acuity Change From Baseline to 10 Weeks (baseline to 10 Weeks); Mean (SD) Change in Visual Acuity in the Amblyopic Eye at the 10 Week Primary Outcome Exam (baseline to 10 Weeks)
B: Visual acuity in the amblyopic eye (6 months)
C: Visual acuity improvement
D: Distribution of Visual Acuity in the Amblyopic Eye at 17 Weeks (17 weeks); Mean Visual Acuity in the Amblyopic Eye at 17 Weeks (17 weeks); Distribution of Change in Visual Acuity in the Amblyopic Eye From Baseline to 17 Weeks (Baseline to 17 weeks); Mean Change in Visual Acuity in the Amblyopic Eye From Baseline to 17 Weeks (Baseline to 17 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available

Extended Follow up of Study Patients

* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care


Options:
A: Visual Acuity of the Amblyopic Eye HOTV (for children <7 y) or ETDRS for children 7+y (2 weeks (for strabismic, anisometropic, and combined mechanism amblyopia); 4 weeks (for deprivation amblyopia))
B: maximal improvement in visual acuity
C: The change of visual acuity from baseline to week six post randomisation visit between the two arms in each group. (6 weeks)
D: Visual acuity in the amblyopic eye (6 months)

Answer: D